Pharmaceutical Company Patient Assistance Programs and Cost-sharing Assistance Programs

What is a Patient Assistance Program (PAP)?
A patient assistance program is a program run through pharmaceutical companies to provide free or low-cost medications to people with low-incomes who do not qualify for any other insurance or assistance programs, such as Medicaid, Medicare, or AIDS Drug Assistance Programs (ADAPs). Each individual company has different eligibility criteria for application and enrollment in their patient assistance program.

HarborPath, a non-profit organization that helps uninsured individuals living with HIV gain access to brand-name prescription medicines at no cost, operates a special patient assistance program for individuals on ADAP waiting lists. An individual is eligible for the HarborPath ADAP waiting list program only if he or she has been deemed eligible for ADAP in his or her state and is verified to be on an ADAP waiting list in that state.

Applying for PAPs
In 2012, the Department of Health and Human Services (DHHS), along with seven pharmaceutical companies, the National Alliance of State and Territorial AIDS Directors (NASTAD), and community stakeholders developed a common patient assistance program application form that can be used by both providers and patients. Before, patients and advocates had to fill out different sets of paperwork for each company; the new application should help simplify this process; however the form still has to be sent to each PAP to receive access to medications. This form combines common information collected on each individual companies form to allow individuals to fill out one form. Once the form is completed, case managers or individuals then submit the single form to each individual company, reducing the overall amount of paperwork necessary to apply for a patient assistance program.

In addition to serving as a special PAP for ADAP waiting list clients, HarborPath also operates as a streamlined, online portal for PAP access. HarborPath creates a single place for application and medication fulfillment. This "one stop shop" portal provides a streamlined, online process to qualify individuals and deliver the donated medications of the participating pharmaceutical companies through a mail-order pharmacy.

What is a Cost-sharing Assistance Program (CAP)?
A cost-sharing assistance program is a program operated by pharmaceutical companies to offer cost-sharing assistance (including deductibles, co-payments and co-insurance) to people with private health insurance to obtain HIV drugs at the pharmacy.

The following provides an overview of PAP contact information, drugs covered, and financial eligibility criteria.

Company	Contact Information	Drugs Covered	Financial Eligibility
AbbVie	800-222-6885 or www.kaletra.com or www.norvir.com	Kaletra and Norvir	500% FPL
Boehringer Ingelheim	800-556-8317 or www.rxhope.com or www.pparx.org	Aptivus and Viramune XR	500% FPL
Bristol-Myers Squibb	888-281-8981 or www.bms.com	Reyataz and Sustiva	300-500% FPL
Genentech	877-757-6243 or www.fuzeon.com	Fuzeon	950% FPL
Gilead Sciences [1]	877-505-6986 or www.atripla.com, www.complera.com, www.genvoya.com, www.odefsey.com, www.stribild.com, www.truvada.com, www.tybost.com, www.viread.com or www.vitekta.com	Atripla, Complera, Emtriva, Genvoya, Odefsey, Stribild, Truvada, Tybost, Viread and Vitekta	500% FPL
Janssen Therapeutics	800-652-6227 or www.jjpaf.org	Edurant, Intelence, Prezista and Prezcobix	200% FPL
Merck and Co.	800-850-3430 or www.merck.com/merckhelps or www.isentress.com	Crixivan and Isentress	500% FPL
ViiV Healthcare	877-784-4842 or www.ViiVhealthcareforyou.com	Combivir, Epivir, Epzicom, Lexiva, Rescriptor, Retrovir, Selzentry, Tivicay, Triumeq, Trizivir, Viracept and Ziagen	500% FPL

---

[1] Effective July 1, 2015, patients who are insured and who do not meet their payer's coverage criteria will no longer be eligible for support via Gilead's patient assistance program. This includes clients whose insurer has limited access based on: step-therapy or clinical criteria (e.g., drug and alcohol testing).

Last Updated: March 7, 2016

The following provides an overview of CAP contact information, drugs covered, and assistance offered.

Company	Contact Information	Drugs Covered	Assistance	Renewal
AbbVie	800-222-6885 or www.kaletra.com or www.norvir.com	Kaletra and Norvir	The co-payment assistance covers the first $200 per Kaletra prescription per month, and the first $150 per Norvir prescription per month.	Must reapply each year.
Bristol-Myers Squibb	888-281-8981 or www.bms.com	Evotaz, Reyataz and Sustiva	The program covers up to $6,800 annually for co-payments, deductibles and co-insurance in all commercially-insured plans for Evotaz, Reyataz and Sustiva.	Must reapply each year.
Bristol-Myers Squibb and Gilead Sciences	888-281-8981 or www.atripla.com	Atripla	The program covers up to $7,500 annually for co-payments, deductibles and co-insurance in all commercially-insured plans for Atripla.	Must reapply each year.
Genentech	866-422-2377 or www.genentech-access.com	Fuzeon	Makes contributions to non-profit programs that will cover co-payments for both private insurance patients and Medicare Part D patients.	N/A
Gilead Sciences [2]	877-505-6986 or www.complera.com, www.genvoya.com, www.stribild.com, www.truvada.com, www.tybost.com, www.viread.com or www.vitekta.com	Complera, Emtriva, Genvoya, Stribild, Truvada, Tybost, Viread and Vitekta	The program covers the first $6,000 per year of co-payments for Complera, Genvoya and Stribild; the first $3,600 per year of co-payments for Truvada; the first $300 per month/$3,600 per year of co-payments for Emtriva, Viread and Vitekta; and the first $50 per month/$600 per year of co-payments for Tybost.	Automatically renews annually for enrolled patients.
Janssen Therapeutics	866-961-7169 or www.edurant.com, www.intelence.com, www.prezista.com or www.prezcobix.com	Edurant, Intelence, Prezista and Prezcobix	The program covers the first $7,500 per year of co-payments, deductibles and co-insurance.	Must reapply each year.
Merck and Co.	855-834-3467 or www.isentress.com	Isentress	The program covers the first $6,600 per year of co-payments for each of 12 eligible prescriptions.	Must reapply after 12 prescriptions filled.
ViiV Healthcare	877-844-8872 or www.mysupportcard.com	Combivir, Epivir, Epzicom, Lexiva, Rescriptor, Retrovir, Selzentry, Tivicay, Trizivir, Triumeq Viracept and Ziagen	The yearly maximum benefit is $6,000 per patient. Tivicay and Triumeq have a $6,000 per year/per patient maximum. Epzicom, Lexiva, Rescriptor, Selzentry and Viracept have a $2,400 per year/per patient maximum.	Must reapply every two years.

---

[2] In March 2016, the US Food and Drug Administration (FDA) approved Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide), a single tablet, three-drug combination produced by Gilead Sciences. At this time, Gilead has not included Odefsey in its cost-sharing assistance programs. Additional information will be included when available.

Last Updated: March 7, 2016

Foundations Providing Access to Care Assistance for People Living with HIV[3]

Needy Meds
http://www.needymeds.org/
Needy Meds offers resources that are helpful to uninsured and underinsured patients including an MRI/CAT scan discount program and medical bill mediation.

Additional Resources

The following resources may be of interest to individuals living with HIV.

Clinical Trials
www.clinicaltrials.gov
A service of the U.S. National Institutes of Health, ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.
Fair Pricing Coalition (FPC)
www.fairpricingcoalition.org
As part of their advocacy work, the Fair Pricing Coalition (FPC) negotiates with companies to ensure that Patient Assistance Programs (PAPs) are adequately generous and easy to apply for.
Health Insurance Marketplace
www.healthcare.gov
The official site of the Health Insurance Marketplace, Healthcare.gov allows individuals and families to sign-up for insurance coverage through the Affordable Care Act.
Treatment Action Group
www.treatmentactiongroup.org
Treatment Action Group collaborates with activists, community members, scientists, governments, and drug companies to make safer, more effective and less toxic treatment for viral hepatitis available.

---

[3] As of March 2016, the Patient Access Network (PAN) Foundation is fully allocated for HIV treatment and prevention; they are therefore no longer accepting or processing applications for new or renewal patients. The PAN Foundation continues to provide support for patients seeking hepatitis C (HCV) treatment.
Last Updated: March 7, 2016